Teacher Retirement System of Texas Has $303,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Teacher Retirement System of Texas lessened its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.5% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 4,526 shares of the specialty pharmaceutical company’s stock after selling 473 shares during the quarter. Teacher Retirement System of Texas’ holdings in ANI Pharmaceuticals were worth $303,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ANIP. Victory Capital Management Inc. lifted its stake in shares of ANI Pharmaceuticals by 6.6% during the 4th quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company’s stock worth $762,000 after buying an additional 858 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth about $3,916,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of ANI Pharmaceuticals by 14.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after buying an additional 1,972 shares during the last quarter. Natixis Advisors LLC lifted its stake in shares of ANI Pharmaceuticals by 2.3% during the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock worth $1,028,000 after buying an additional 417 shares during the last quarter. Finally, Intech Investment Management LLC lifted its stake in shares of ANI Pharmaceuticals by 41.2% during the 4th quarter. Intech Investment Management LLC now owns 17,780 shares of the specialty pharmaceutical company’s stock worth $983,000 after buying an additional 5,187 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright began coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 10th. They set a “buy” rating and a $84.00 price target on the stock. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.88.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $66.30 on Friday. The company has a quick ratio of 1.98, a current ratio of 2.66 and a debt-to-equity ratio of 1.46. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The firm has a market cap of $1.44 billion, a P/E ratio of -52.20 and a beta of 0.57. The company’s 50-day moving average price is $62.88 and its two-hundred day moving average price is $62.65.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same period last year, the firm earned $0.82 EPS. The business’s quarterly revenue was up 43.4% compared to the same quarter last year. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider directly owned 107,317 shares of the company’s stock, valued at $6,487,312.65. This trade represents a 3.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Ori Gutwerg sold 881 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president directly owned 89,897 shares in the company, valued at $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock valued at $345,222 in the last ninety days. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.